BlueRock’s Phase I Study with Bemdaneprocel in Parkinson’s Disease Patients Achieves Main Goal
BlueRock Therapeutics, in collaboration with Bayer AG, recently announced the successful results of their Phase I clinical trial for bemdaneprocel (BRT-DA01), an innovative cellular therapy derived from stem cells, aimed at treating Parkinson’s disease. The findings were presented at the International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark. Key Highlights: Dr. Claire […]
Developing Regenerative Medicines featuring Dr. Stefan Irion
In episode 228 of the Stem Cell Podcast, Dr. Dayklin James and Dr. Arun Sharma chat with Dr. Stefan Irion, Senior Vice President of Research at BlueRock Therapeutics, a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. He talks about the company’s Parkinson’s disease trial and the challenges […]